Targeting CSF1R in Chronic GVHD — Lessons in Translation

This is the authors' abstract. We don't add key points for this paper.

Chronic graft-versus-host disease (GVHD) remains a rare and unacceptably debilitating autoimmune-like syndrome that afflicts patients in whom a blood disorder or cancer is otherwise cured by means of allogeneic hematopoietic stem-cell transplantation (HSCT). After allogeneic HSCT is performed, ongoing loss of T-cell and B-cell immune tolerance occurs as a new immune system develops under constant exposure to foreign host and tumor antigens. Patients with chronic GVHD can have hallmark fibrotic features such as scleroderma and lung fibrosis that are typically refractory to classic immunosuppressants. 1 More details on chronic GVHD can be found in the editorial by Mohty in this issue . . .